Concise overview articles of key topics in neurodegeneration, which can be read wherever you are, whenever suits you.
Find out more here.
Announcing the launch of Mini Reviews
New Thematic Series - AI in Dementia
Alzheimer's Research & Therapy presents a thematic series focusing on the use of artificial intelligence, machine learning and related techniques in dementia research.
Find out more about the series here.
Articles
-
-
Subjective cognitive concerns, APOE ε4, PTSD symptoms, and risk for dementia among older veterans
-
The criteria used to rule out mild cognitive impairment impact dementia incidence rates in subjective cognitive decline
-
Comparison of plasma soluble and extracellular vesicles-associated biomarkers in Alzheimer’s disease patients and cognitively normal individuals
-
The cognitive effect of non-invasive brain stimulation combined with cognitive training in Alzheimer’s disease and mild cognitive impairment: a systematic review and meta-analysis
-
Stem cell factor and granulocyte colony-stimulating factor reduce β-amyloid deposits in the brains of APP/PS1 transgenic mice
-
Cerebral microbleeds: overview and implications in cognitive impairment
-
BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease
-
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
The Correction to this article has been published in Alzheimer's Research & Therapy 2022 14:70
-
Alzheimer’s disease drug-development pipeline: few candidates, frequent failures
Early Career Researcher Reviewer Panel
Interested in an introduction to peer reviewing articles for Alzheimer's Research & Therapy?
Find out more about our ECR Peer Reviewer Panel!
Aims and scope
Alzheimer's Research & Therapy is the major forum for translational research into Alzheimer's disease. An international peer-reviewed journal, it publishes open access basic research with a translational focus, as well as clinical trials, research into drug discovery and development, and epidemiologic studies. The journal also provides reviews, viewpoints, commentaries, debates and reports.
Although the primary focus is Alzheimer's disease, the scope encompasses translational research into other neurodegenerative diseases.
Published Thematic Series
Latest Tweets
View Twitter timeline
Your browser needs to have JavaScript enabled to view this timeline
Alzheimer's blogs from BMC
Failed to load RSS feed.
Affiliated with
Annual Journal Metrics
-
Citation Impact 2023
Journal Impact Factor: 7.9
5-year Journal Impact Factor: 8.3
Source Normalized Impact per Paper (SNIP): 1.687
SCImago Journal Rank (SJR): 2.608
Speed 2023
Submission to first editorial decision (median days): 11
Submission to acceptance (median days): 152
Usage 2023
Downloads: 1,914,774
Altmetric mentions: 2,982